본문으로 건너뛰기
← 뒤로

Metachronous papillary thyroid carcinoma and hereditary breast carcinoma with BRCA1 mutation in a Vietnamese woman: A case report.

증례보고 1/5 보강
International journal of surgery case reports 2023 Vol.106() p. 108249
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: BRCA1 germline variants, which belong to the DNA DSB repair system, there may be a genetic susceptibility to thyroid cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
A hypothesis is breast cancer with BRCA1 mutation increases the risk of thyroid cancer. [CONCLUSION] Understanding the relationship between breast and thyroid cancer helps clinicians for well management of both diseases and also contributes to the development of new preventive strategies, diagnostics and therapeutics as so as a new research direction.

Nguyen TMT, Pham HNH, Do TA, Pham KH, Van Nguyen C

📝 환자 설명용 한 줄

[INTRODUCTION AND IMPORTANCE] Papillary thyroid carcinoma is the most common type of malignancy in endocrine tumor.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Nguyen TMT, Pham HNH, et al. (2023). Metachronous papillary thyroid carcinoma and hereditary breast carcinoma with BRCA1 mutation in a Vietnamese woman: A case report.. International journal of surgery case reports, 106, 108249. https://doi.org/10.1016/j.ijscr.2023.108249
MLA Nguyen TMT, et al.. "Metachronous papillary thyroid carcinoma and hereditary breast carcinoma with BRCA1 mutation in a Vietnamese woman: A case report.." International journal of surgery case reports, vol. 106, 2023, pp. 108249.
PMID 37094417

Abstract

[INTRODUCTION AND IMPORTANCE] Papillary thyroid carcinoma is the most common type of malignancy in endocrine tumor. Women with breast cancer have an increased risk of developing thyroid cancer. Especially, patients with BRCA1 germline variants, which belong to the DNA DSB repair system, there may be a genetic susceptibility to thyroid cancer.

[CASE PRESENTATION] This study investigated a 47-year-old Vietnamese female patient with BRCA1 mutation, namely NM_007294.3 (BRCA1): c.4998insA (p. Tyr1666Terfs), who developed PTC after one year of breast cancer treatment.

[CLINICAL DISCUSSION] Factors that are thought to increase the risk of thyroid cancer after breast cancer treatment include treatment methods, hormonal factors, genetic susceptibility, and others. A hypothesis is breast cancer with BRCA1 mutation increases the risk of thyroid cancer.

[CONCLUSION] Understanding the relationship between breast and thyroid cancer helps clinicians for well management of both diseases and also contributes to the development of new preventive strategies, diagnostics and therapeutics as so as a new research direction.